Jersey Shore University Medical Center Joins APOLLO Trial
Evaluating the Intrepid Transcatheter Mitral Valve Replacement System for patients with severe symptomatic mitral regurgitation
Hackensack Meridian Jersey Shore University Medical Center recently joined the APOLLO trial to evaluate the safety and efficacy of the Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System (TMVR).
The invitation to join the APOLLO trial follows Jersey Shore University Medical Center’s participation in other significant clinical trials for new approaches in structural heart disease treatments, including the PROGRESS, Optimize Pro, Protected TAVR, and MitraClip Repair MR trials respectively.
The APOLLO study is evaluating the TMVR device in patients with moderate to severe symptomatic mitral regurgitation (MR), with or without mitral annular calcification (MAC), who are unsuitable for either transcatheter edge-edge repair (TEER) with MitraClip or surgical mitral valve interventions.
The Intrepid TMVR integrates self-expanding stent technology with a tissue heart valve to facilitate minimally invasive, catheter-based implantation. It is designed to engage and conform to the native annulus without need for additional sutures, tethers or anchors. The prosthesis is compressed inside a hollow delivery catheter and implantation is completed through either transapical or transfemoral venous access.
Learn more about innovative heart and vascular treatments at Jersey Shore University Medical Center.